Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases.
about
Multiple Molecular Pathways in Melanomagenesis: Characterization of Therapeutic TargetsMelanoma Brain Metastasis: Mechanisms, Models, and MedicineManaging leptomeningeal melanoma metastases in the era of immune and targeted therapy.Combinatorial drug screening and molecular profiling reveal diverse mechanisms of intrinsic and adaptive resistance to BRAF inhibition in V600E BRAF mutant melanomas.High intensity focused ultrasound inhibits melanoma cell migration and metastasis through attenuating microRNA-21-mediated PTEN suppression.Transmigration characteristics of breast cancer and melanoma cells through the brain endothelium: Role of Rac and PI3K.[Melanoma brain metastases : Treatment options].Molecular profiling of patient-matched brain and extracranial melanoma metastases implicates the PI3K pathway as a therapeutic targetComplete loss of PTEN protein expression correlates with shorter time to brain metastasis and survival in stage IIIB/C melanoma patients with BRAFV600 mutationsElongation factor-2 kinase regulates TG2/β1 integrin/Src/uPAR pathway and epithelial-mesenchymal transition mediating pancreatic cancer cells invasionA Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases.Next-Generation Sequencing of Stage IV Squamous Cell Lung Cancers Reveals an Association of PI3K Aberrations and Evidence of Clonal Heterogeneity in Patients with Brain Metastases.Extrinsic factors can mediate resistance to BRAF inhibition in central nervous system melanoma metastasesMelanoma metastases caught in the AKTEvaluating Cancer of the Central Nervous System Through Next-Generation Sequencing of Cerebrospinal FluidExpression of Phosphatase and Tensin Homologue, phospho-Akt, and p53 in Acral Benign and Malignant Melanocytic Neoplasms (Benign Nevi, Dysplastic Nevi, and Acral Melanomas)Pathologic and gene expression features of metastatic melanomas to the brainSynergistic anti-glioma effect of a coloaded nano-drug delivery system.Longitudinal study of recurrent metastatic melanoma cell lines underscores the individuality of cancer biology.Navigating the therapeutic complexity of PI3K pathway inhibition in melanoma.Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial.Molecular insights into melanoma brain metastases.Melanoma Brain Metastases: Current Areas of Investigation and Future Directions.Melanoma central nervous system metastases: current approaches, challenges, and opportunities.Metastasis as an evolutionary process.The Promise of Molecularly Targeted and Immunotherapy for Advanced Melanoma.Melanoma tumors frequently acquire LRP2/megalin expression, which modulates melanoma cell proliferation and survival rates.Converting biology into clinical benefit: lessons learned from BRAF inhibitors.Tumor-associated fibroblast-conditioned medium induces CDDP resistance in HNSCC cells.Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTENLeptomeningeal Disease and the Evolving Role of Molecular Targeted Therapy and Immunotherapy.The biology and therapeutic management of melanoma brain metastases.Herbacetin suppresses cutaneous squamous cell carcinoma and melanoma cell growth by targeting AKT and ODC.Improved survival of patients with melanoma brain metastases in the era of targeted BRAF and immune checkpoint therapies.Foe or friend? Janus-faces of the neurovascular unit in the formation of brain metastases.Survival patterns following brain metastases for patients with melanoma in the MAP-kinase inhibitor era.Drug resistance in HER2-positive breast cancer brain metastases: blame the barrier or the brain?Targeting the duality of cancer.[Tumor Cells and Micro-environment in Brain Metastases].Deciphering mechanisms of brain metastasis in melanoma - the gist of the matter
P2860
Q26795735-3B786F78-BD4B-40C6-9646-0533248A147CQ28069421-05FDF1D9-D664-4EA2-B16D-541BE1EAF3CFQ30251581-FB939B58-2018-45D1-9BF7-00C07DE4644DQ30277902-C4593234-A4A0-443B-9E78-EBB7092286FBQ30365568-84CCEA00-210E-480B-8C67-0662391BD61CQ30787310-26DAFE88-1E23-4618-84D6-FA8B62D53F78Q31098294-137F86B8-BFF9-4408-9483-873B0D92C817Q34438536-12DC5622-9E75-4FDB-9F52-38FF1353B2E3Q34438555-653803A0-15AC-47C6-BC24-B50B27E9448DQ34473662-A6A99283-1232-49F9-811B-120FE95455D8Q35820476-458748AA-9D3F-46EF-A381-5E2E6B9990C1Q36274943-E66807E5-2BAD-43F4-A209-2CA43B9CACECQ36533041-B25FEDFC-B1A7-49E9-89FB-61F5B5B8158FQ36998064-E09F0C2A-DD8F-4CC2-B1F3-59A262900151Q37168845-AA4C010C-15B8-4A6A-931F-B5F9081C6928Q37339357-C8954B02-8361-4A4A-A574-73C08A079543Q37512029-BC4326C5-37AA-445C-81CC-F1CF5EF24F91Q37527883-367974AC-2F39-4DED-922A-F4A624410AA5Q37707106-783591BE-B5A7-40B7-ADDB-678F3EC18C00Q38148747-48558A5A-C474-482E-A770-FC30B5268092Q38737680-E783E443-2BDC-4096-BD82-09B023E7F3C2Q38764364-2ADD13E1-1D7F-466D-AFB4-9F6F1387F078Q38766796-02B0069C-31CC-40EB-A1B8-F70B29153105Q38807942-B6493474-7333-443E-8054-FF95A237D784Q38819909-720DFFA3-971F-4669-B07A-97E7E5AB8F1EQ38909389-A54AA884-C9D9-43F4-BE4F-B31F766F23D5Q38920389-9720BD89-FCAE-49C8-BBEC-6E958B5E6340Q38940098-88A836A8-2353-47FD-BA16-F41C70473B85Q39924257-E6FF2FCA-9D91-436A-BE63-4058CC7BB3FBQ41593039-7366C55D-20C7-4DE9-B354-6CFCB27FBA32Q47133535-93C9C500-D532-4FD0-950A-2E1FB6D62826Q47247953-FBAB97E0-FB80-497C-8F30-1C869552B843Q47613853-118682EE-A553-4CD3-AA83-8E4FF3C03FC0Q47653459-871254A2-6375-4343-B663-BAC9D5A9DF67Q48108646-83BE2754-E365-4F45-86D0-1233FD898D68Q48234725-7FB54369-73B3-4357-8227-D8A6B1CDD039Q50043843-6DC4B751-7310-4EA9-97FD-E9200D142A22Q52539731-78BB8562-E2FE-4747-AFE0-D5063A796444Q53022125-EB0A5BB4-FE14-4CFB-9B0B-B78D574F2F51Q56673276-E95F8AAF-562B-40A0-AD1A-4BA4F59B6328
P2860
Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 03 February 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Targeting hyperactivation of t ...... of melanoma brain metastases.
@en
Targeting hyperactivation of t ...... of melanoma brain metastases.
@nl
type
label
Targeting hyperactivation of t ...... of melanoma brain metastases.
@en
Targeting hyperactivation of t ...... of melanoma brain metastases.
@nl
prefLabel
Targeting hyperactivation of t ...... of melanoma brain metastases.
@en
Targeting hyperactivation of t ...... of melanoma brain metastases.
@nl
P2093
P2860
P50
P356
P1433
P1476
Targeting hyperactivation of t ...... of melanoma brain metastases.
@en
P2093
Alexander Roesch
Andrea Forschner
Annemarie Adam
Antje Bornemann
Benjamin Weide
Bernhard Klumpp
Claus Garbe
Cornelia Mauch
Dagmar Kulms
Daniela Beck
P2860
P356
10.1002/CAM4.50
P407
P577
2013-02-03T00:00:00Z